Praxis Precision Medicines, INC Form 4 insider transactions

Praxis Precision Medicines CEO Marcio Souza gifted 400 shares of common stock to a charitable fund.

Praxis Precision Medicines' Chief Financial Officer, Timothy Kelly, acquired 384 shares of common stock through an employee stock purchase plan.

Praxis Precision Medicines' General Counsel, Alex Nemiroff, executed a series of stock option exercises and subsequent sales of common stock for estate planning purposes, resulting in no net change to his beneficial ownership.

Praxis Precision Medicines' Principal Accounting Officer, Lauren Mastrocola, sold common stock on November 20, 2025, following option exercises, for estate planning purposes.

Adage Capital Management, a 10% owner and director, sold 313,910 shares of Praxis Precision Medicines common stock on October 16, 2025.

Praxis Precision Medicines director Dean J. Mitchell exercised stock options to acquire common stock under a Rule 10b5-1 plan.

Dean J Mitchell, a Director at Praxis Precision Medicines, Inc., has acquired 10,520 stock options with an exercise price of $44.04, vesting over one year.

Praxis Precision Medicines, Inc. Director William D. Young was granted 10,520 stock options with an exercise price of $44.04, vesting over one year starting June 26, 2025.

Praxis Precision Medicines, Inc. Director Gregory Norden was granted 10,520 stock options with an exercise price of $44.04, vesting monthly over one year starting June 26, 2025.

Praxis Precision Medicines, Inc. Director Jill DeSimone was granted 10,520 stock options with an exercise price of $44.04, vesting monthly over one year starting June 26, 2025.

Jeffrey Chodakewitz, a Director at Praxis Precision Medicines, Inc. (PRAX), was granted 10,520 stock options with an exercise price of $44.04 per share, vesting over one year.

Merit Ester Cudkowicz, a Director at Praxis Precision Medicines, Inc., was granted 10,520 stock options with an exercise price of $44.04, vesting monthly over one year starting June 26, 2025.

Praxis Precision Medicines CEO Marcio Souza reports acquiring 348 shares of common stock through the company's Employee Stock Purchase Plan at a price of $31.535 per share.

Chief Financial Officer Timothy Edwin Kelly reports acquiring and disposing of Praxis Precision Medicines, Inc. common stock on May 14, 2025.

Alex Nemiroff, General Counsel and Secretary of Praxis Precision Medicines, reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, reports the disposal of 40 shares of common stock to cover tax obligations related to vesting restricted stock units.

CEO Marcio Souza reports disposition of 401 shares of Praxis Precision Medicines common stock to cover tax obligations related to vesting restricted stock units.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, received stock options and restricted stock units, and also had shares withheld for tax obligations.

Praxis Precision Medicines CEO, Marcio Souza, received 37,500 restricted stock units and options for 75,000 shares on January 10, 2025.

Praxis Precision Medicines' Chief Financial Officer, Timothy Kelly, reported the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover tax obligations.

Praxis Precision Medicines' General Counsel and Secretary, Alex Nemiroff, reports the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover tax obligations.

Praxis Precision Medicines CEO, Marcio Souza, sold 434 shares of common stock to cover tax obligations related to vesting restricted share units.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, sold 35 shares to cover tax obligations related to vesting restricted share units.

Alex Nemiroff, General Counsel and Secretary of Praxis Precision Medicines, sold 89 shares to cover tax obligations related to vesting restricted share units.

Praxis Precision Medicines' Chief Financial Officer, Timothy Edwin Kelly, sold 139 shares of common stock to cover tax obligations related to vesting restricted share units.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, acquired 294 shares of common stock through the company's Employee Stock Purchase Plan.

Praxis Precision Medicines' Chief Financial Officer, Timothy Edwin Kelly, acquired 205 shares of common stock through the company's Employee Stock Purchase Plan.

A Praxis Precision Medicines executive, Alex Nemiroff, exercised stock options and sold a portion of the acquired shares for estate planning purposes.

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, exercised stock options and sold shares for estate planning purposes.

Praxis Precision Medicines CEO Marcio Souza acquired 185,000 stock options on July 29, 2024, according to a Form 4 filing with the SEC.